Forest's depression drug Fetzima wins US approval
This article was originally published in Scrip
Executive Summary
The US FDA on 26 July gave its approval to Forest Laboratories to market Fetzima (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, as a treatment for adults with major depressive disorder (MDD), a serious medical condition in which feelings of sadness and other symptoms occur nearly every day for at least two weeks and interfere with a person's ability to work, sleep, study, eat and enjoy once-pleasurable activities.